Your session is about to expire
← Back to Search
Sacituzumab Govitecan + Pembrolizumab for Breast Cancer
Study Summary
This trial studies if two drugs can help treat early-stage triple negative breast cancer that is not responding to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had any live vaccines in the last 30 days.I have an autoimmune disease needing treatment or need medicine to suppress my immune system.My breast cancer is in the early stages and has been confirmed by a lab test.My cancer is either not responsive to hormones or barely responsive, and does not have too much HER2.My tumor size hasn’t changed or has grown after starting the KN-522 treatment.I agree to have a biopsy after my initial cancer treatment.I have HIV or hepatitis but meet the specific conditions for treatment eligibility.I have had issues with my digestive system or a history of colitis.I have not had a heart attack or severe heart issues in the last 6 months.My organ functions are within normal ranges according to recent tests.I have not received any cancer treatments for my current diagnosis.I started treatment with pembrolizumab and chemotherapy (paclitaxel + carboplatin).I have difficulty with memory or thinking clearly.I am 18 years old or older.I don't have health issues that would affect my immunotherapy treatment.I am not pregnant or incapable of becoming pregnant.My condition is at stage IV.I am fully active or can carry out light work.
- Group 1: Sacituzumab Govitecan and Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How hazardous are Sacituzumab Govitecan and Pembrolizumab to patients' health?
"Our assessment of the safety profiles for Sacituzumab Govitecan and Pembrolizumab, based on Phase 2 trial results, is a score of 2 since there are some data supporting its security but none that support its efficacy."
Are there any vacancies currently available for this medical trial?
"Reports from clinicaltrials.gov state that this particular research is not currently enrolling any participants, despite its initial posting date of June 30th 2023 and last update on December 22nd 2022. Nevertheless, there are plenty of other medical studies actively seeking candidates at the moment; approximately 2564 in total."
Share this study with friends
Copy Link
Messenger